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Abstract	  
	  
	   For	   nearly	   forty	   years	   significant	   research	   has	   been	   carried	   out	   on	  retinylidene	  proteins	   for	  use	   in	  device	  applications.	   	  Halorhodopsin	   (HR),	  a	  light-­‐activated	   chloride	   ion	   pump,	   demonstrates	   potential	   for	   use	   as	   the	  scaffolding	   in	   an	   artificial	   retina.	   	   Retinal	   implants	   are	   needed	   to	   restore	  vision	   to	   people	   afflicted	   with	   ophthalmic	   diseases,	   such	   as	   age-­‐related	  macular	  degeneration	  (AMD)	  and	  retinitis	  pigmentosa	  (RP).	  	  A	  protein-­‐based	  chloride	  ion-­‐patch	  would	  be	  utilized	  by	  the	  eye	  to	  create	  an	  influx	  of	  chloride	  ions,	  similar	  to	  ion	  concentrations	  in	  healthy	  retinas	  during	  the	  conversion	  of	  light	  stimuli	  to	  electrochemical	  signals.	  	  This	  protein-­‐based	  retinal	  prosthesis	  will	  directly	  stimulate	  the	  bipolar	  cells	  of	  the	  retina,	  replacing	  the	  function	  of	  damaged	  photoreceptor	  cells.	  	  Other	  alternative	  treatments	  for	  AMD	  and	  RP	  involve	   invasive	   surgeries	   to	   implant	   microelectronic	   devices	   that	   are	  frequently	   supplemented	   with	   external	   components.	   	   Comparatively,	   the	  artificial	  retina	  under	  investigation,	  comprised	  of	  a	  medically	  inert	  substrate	  layered	  with	  HR,	  provides	  a	  more	  practical,	  less	  surgically	  invasive	  approach	  to	  provide	  higher	  resolution	  vision	  to	  patients.	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1. Introduction	  
1.1. Need	  For	  Artificial	  Retina	  As	  the	  average	  lifespan	  continually	  increases,	  age-­‐related	  diseases	  and	  ailments	  are	  becoming	  more	  prevalent.	   	  Retinal	  degenerative	  diseases,	  such	  as	   age-­‐related	   macular	   degeneration	   (AMD)	   and	   retinitis	   pigmentosa	   (RP)	  are	  especially	  devastating	  and	  commonly	   found	   in	   the	  elder	  population.	   	   In	  fact,	   AMD	   affects	   more	   than	   one-­‐third	   of	   the	   elderly	   population	   in	   the	  western	  world	  and	  is	  the	  principle	  cause	  of	  irreversible	  vision	  loss	  (1).	  	  This	  statistic	  is	  predicted	  to	  only	  increase	  as	  the	  life	  expectancy	  of	  the	  population	  increases	  (1,	  2).	  	  Age-­‐related	  macular	  degeneration	  is	  caused	  by	  deterioration	  of	  the	  central	  portion	  of	  the	  retina,	  leading	  to	  a	  loss	  of	  central	  vision	  resulting	  in	  difficulties	  with	  tasks	  that	  require	  high-­‐contrast	  vision	  such	  as	  reading	  and	  driving	  (3)	  (Figure	  1).	  	  Retinitis	  pigmentosa,	  the	  other	  major	  cause	  of	  vision	  loss	   and	   blindness	   in	   the	   elderly,	   is	   caused	   by	   a	   diverse	   group	   of	   genetic	  mutations	  in	  rods	  and	  is	  characterized	  by	  a	  progressive	  loss	  of	  visual	  acuity	  resulting	   from	   photoreceptor	   death.	   	   This	   currently	   incurable	   disease	   is	   in	  the	  rod	  photoreceptor	  cells.	   	  Patients	  with	  RP	  often	  have	  difficulty	  seeing	  in	  the	   dark,	  which	   is	   commonly	   referred	   to	   as	   night	   blindness,	   followed	   by	   a	  reduction	  of	   the	  peripheral	   vision,	   and	  ultimately,	   blindness	   (4)	   (Figure	  1).	  	  Globally,	   retinitis	   pigmentosa	   affects	   more	   than	   1	   million	   individuals,	   a	  prevalence	  of	  about	  1	  in	  4,000	  people	  (4).	  	  Visual	  impairment	  from	  AMD	  and	  RP	   significantly	   reduces	   the	   quality	   of	   life	   in	   patients	   of	   older	   generations	  and	   is	   associated	   with	   disability	   and	   clinical	   depression	   in	   patients	   (2).	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Retinal	  prostheses	  offer	  a	  viable	  treatment	  option	  to	  restoring	  and	  improving	  vision,	  and	  therefore,	  the	  lives	  of	  those	  afflicted	  with	  ophthalmic	  diseases.	  
	  
	  
Figure	   1:	  Comparison	  of	  vision	   in	  a	  healthy	   retina	  and	   in	  diseased	   retinas.	  	  Vision	   as	   seen	   in	   a	   healthy	   retina	   (A)	   and	   retinas	   affected	   with	   ocular	  diseases	  (B	  and	  C).	   	  The	  middle	  image	  (B)	  demonstrates	  the	  loss	  of	   focused	  pixels	  in	  the	  central	  region	  of	  vision,	  which	  is	  characteristic	  of	  advanced	  age-­‐related	   macular	   degeneration.	   	   The	   bottom	   image	   (C)	   is	   representative	   of	  tunnel	   vision,	   typical	   of	   a	   patient	   afflicted	   with	   progressed	   retinitis	  pigmentosa.	  
	   3	  
1.2. Anatomy	  of	  the	  Eye	  The	  eye	  is	  a	  complex	  organ	  that	  captures	  and	  analyzes	  light	  and	  then	  sends	   vast	   amounts	   of	   sensory	   information	   to	   the	   brain.	   	   In	   the	   vertebrate	  eye,	  light	  enters	  through	  the	  pupil	  and	  is	  focused	  on	  a	  highly	  organized	  array	  of	   light	   sensitive	  neurons	   in	   the	   retina.	   	  The	   retina,	   a	   concave	  multilayered	  tissue	  that	  lines	  the	  inner	  back	  of	  the	  eye,	  contains	  a	  complex	  neural	  circuitry	  used	  to	  convert	  the	  graded	  electrical	  activity	  of	  the	  photoreceptor	  cells	  into	  a	  series	   of	   action	  potentials,	  which	   travel	   via	   axons	   in	   the	   optic	   nerve	   to	   the	  brain	  (5)	  (Figure	  2).	  Photoreceptors	   are	   the	   light	   sensitive	   neurons	   of	   the	   retina.	   	   These	  cells	  are	  broadly	  categorized	  as	  either	  rods	  or	  cones,	  but	  can	  be	  distinguished	  by	   shape,	   type	   of	   pigment	   they	   contain,	   distribution	   across	   the	   retina,	   and	  pattern	   of	   synaptic	   connections	   (6)	   (Figure	   3).	   	   Rods	   contain	   the	  photopigment,	   rhodopsin,	   which	   is	   highly	   sensitive	   to	   light	   allowing	   these	  photoreceptor	   cells	   to	   function	   advantageously	   under	   low,	   or	   dim,	   light	  conditions	  for	  night	  and	  peripheral	  vision	  (7).	  	  Cones	  contain	  photopigments	  that	  are	  sensitive	  to	  bright	  light	  and	  can	  detect	  color	  (7).	  Bipolar	   cells,	   anterior	   to	   the	   layer	  of	  photoreceptors,	   have	   two	  axon	  extensions	   that	   connect	   the	   photosensory	   signaling	   cascade	   from	   the	  photoreceptors	   to	   the	   ganglion	   cells,	   which	   are	   found	   in	   an	   adjacent	   cell	  layer.	   	   Ganglion	   cells	   then	   relay	   sensory	   information	   from	   the	   eye	   to	   the	  brain.	  	  In	  a	  young,	  healthy	  eye,	  reflected	  light	  enters	  the	  eye	  and	  is	  focused	  on	  the	   retina.	   	   Photoreceptors	   then	   convert	   light	   into	   electrical	   signals,	   or	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Figure	  2:	  Anatomy	  of	  the	  Eye	  and	  Layers	  of	  the	  Retina.	  	  The	  visual	  system	  of	  humans	  showing	  key	  anatomical	  components	  of	  the	  eye	  (a)	  and	  the	  layers	  of	  highly	   organized	   neural	   circuitry	   and	   light	   sensitive	   photoreceptor	   cells	   of	  the	  retina	  (b).	  	  	  




































Figure	   3:	   Detailed	   Representation	   of	   Rods	   and	   Cones.	   	   This	   modified	   oil	  painting	  by	  German	  artist	  Martin	  Missfeldt,	  1993,	  shows	  the	  clear	  distinction	  in	   shape	  between	  rod	   (left)	  and	  cone	   (right)	  photoreceptor	   cells.	   	  Rods	  are	  responsible	  for	  dim	  or	   low	  light	  vision	  and	  cones	  are	  responsible	  for	  bright	  light	  and	  color	  vision.	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1.3. Retinal	  Degenerative	  Diseases	  The	  macula	  is	  the	  central,	  posterior	  portion	  of	  the	  retina,	  and	  contains	  the	   densest	   concentration	   of	   photoreceptors.	   	   This	   region	   of	   the	   eye	   is	  responsible	   for	   allowing	   a	   person	   to	   read,	   see	   fine	   detail,	   and	   to	   recognize	  faces	   (3).	   	   Age-­‐related	   macular	   degeneration	   primarily	   affects	   the	  photoreceptors	   found	   in	   the	  macula,	   leading	   to	   central	   vision	   impairment,	  which	  hinders	  the	  ability	  for	  patients	  to	  achieve	  simple	  day-­‐to-­‐day	  tasks.	  Photoreceptor	  degeneration	  due	  to	  AMD	  is	  caused	  by	  both	  genetic	  and	  environmental	   factors.	   	  There	  are	  two	  classifications	  of	  advanced	  AMD:	  wet	  macular	   degeneration,	   and	   dry	   macular	   degeneration	   (3).	   	   Wet	   AMD,	   also	  known	   as	   neovascular	   or	   exudative,	   occurs	   as	   a	   result	   of	   the	   abnormal	  growth	  of	  blood	  vessels	  that	  are	  directed	  towards	  the	  macula,	  which	  in	  turn	  causes	   the	   retinal	   pigment	   epithelium	   to	   become	   detached	   (9).	   	  Wet	   AMD,	  while	   less	   prevalent	   comparatively	   to	   dry	   AMD,	   is	   often	   associated	   with	  severe	  vision	  loss.	  	  Dry	  AMD	  results	  from	  the	  aging	  and	  thinning	  of	  the	  retina,	  specifically	   in	   the	  macula.	   	   The	   early	   stages	   of	   dry	   AMD	   can	   be	   diagnosed	  when	  drusen,	  yellow	  deposits	  composed	  of	  mainly	   fat	  and	  protein,	  begin	  to	  accumulate	  in	  and	  around	  the	  macula	  (3).	  	  The	  advanced,	  or	  late	  form	  of	  dry	  AMD	   is	   characterized	  by	  gradual	   geographic	  atrophy,	   the	  degeneration	  and	  death	  of	  rod	  and	  cone	  cells	   in	  the	  macula,	  as	  well	  as	  the	  presence	  of	   larger,	  more	  obtrusive	  drusen	  (10)	  (Figure	  4).	  	  To	  date,	  there	  is	  no	  cure	  for	  AMD	  (1-­‐
3).	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Figure	  4:	  Progression	  of	  AMD	  through	  the	  view	  of	  an	  ophthalmoscope.	  	  This	  figure	  from	  de	  Jong’s	  AMD	  review	  article	  (10)	  provides	  a	  view	  of	  the	  retina	  as	  AMD	   progresses.	   	   The	   first	   four	   panels	   (A-­‐D)	   show	   drusen	   present	   in	  progressive	  sizes	  and	  quantities	  (as	  indicated	  by	  the	  black	  arrows)	  in	  retinas	  diagnosed	   with	   dry	   age-­‐related	  macular	   degeneration.	   	   Panels	   (E)	   and	   (F)	  depict	   advanced,	   or	   late	   stage,	   wet	   AMD	   with	   serious	   detachment	   of	   the	  retinal	   pigment	   epithelium	  as	  outlined	  by	   the	   arrowheads.	   	   Panels	   (F),	   (G),	  and	  (H)	  demonstrate	  late	  AMD	  and	  the	  remnants	  of	  subretinal	  hemorrhages.	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Retinitis	   pigmentosa	   is	   the	   term	   for	   a	   type	   of	   progressive	   retinal	  dystrophy	  in	  which	  there	  are	  groups	  of	  inherited	  genetic	  abnormalities	  of	  the	  photoreceptors.	  	  While	  RP	  involves	  the	  accumulation	  of	  pigmentation	  and	  the	  gradual	   loss	   of	   both	   photoreceptor	   types,	   typically	   rods	   are	   affected	   first	  (Figure	  5).	  	  Patients	  afflicted	  with	  RP	  usually	  experience	  night	  blindness	  and	  loss	   of	   peripheral	   vision	   as	   the	   initial	   symptoms	   because	   the	   rods	   are	  concentrated	   in	   the	   outer	   portion	   of	   the	   retina	   and	   mediate	   achromatic	  vision	   in	  dim	   light	   (4).	   	  Most	  patients	   suffering	   from	  diagnosis	  with	  RP	  are	  considered	   legally	  blind	  by	  age	  40	  because	  of	   tunnel	   vision,	  which	   leads	   to	  severely	  constricted	  visual	  fields.	  	  As	  RP	  continues	  to	  advance,	  the	  cone	  cells	  are	   affected	   in	   a	  mechanism	   not	   yet	   fully	   understood,	   and	   the	   patient	  will	  ultimately	   lose	   remaining	   eyesight,	   central	   vision,	   by	   age	   60	   (4,	   11).	  	  Ophthalmic	   diseases	   such	   as	   AMD	   and	   RP	   severely	   attenuate	   the	   outer	  nuclear	  layer	  of	  the	  retina,	  which	  contains	  the	  rod	  and	  cone	  photoreceptors	  (2,	  4).	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Figure	   5:	   Fundus	   photograph	   of	   retinitis	   pigmentosa.	   	   This	   figure	   from	  Duane’s	  Ophthalmology	   (12)	   shows	   the	   early	   stages	   of	   RP	   as	   pigmentation	  starts	   to	  accumulate	  and	  blood	  vessels	  begin	   to	   thin	   (A).	   	  Late	  stages	  of	  RP	  can	  be	  observed	  as	  large	  clumps	  of	  pigmentation	  with	  attenuated	  and	  sparse	  blood	  vessels	  (B).	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1.4. Proposed	  Treatments	  for	  AMD	  and	  RP	  Presently,	  significant	  research	  efforts	  are	  being	  made	  in	  developing	  a	  means	  to	  restore	  vision	  to	  those	  with	  impairments	  such	  as	  AMD	  and	  RP	  (11,	  
13-­‐20).	   	   To	  date	   there	   are	  no	   cures	   for	  AMD	  or	  RP,	   however,	   gene	   therapy	  techniques	  and	  recently	  developed	  medical	  device	  technologies	  offer	  a	  viable	  options	  for	  providing	  some	  degree	  of	  improved	  vision	  and	  an	  increase	  in	  the	  quality	  of	  life	  for	  these	  patients.	  	  	  Gene	   therapy,	   a	   type	   of	   genetic	   engineering	   that	   involves	   the	  insertion,	   deletion,	   or	   correction	   of	   a	   gene	   responsible	   for	   specific	   protein	  functions,	  is	  achieved	  through	  the	  use	  of	  a	  carrier	  molecule	  called	  a	  vector	  to	  deliver	   the	   therapeutic	   gene	   to	   the	   target	   cells.	   	   Currently,	   the	   most	  commonly	   used	   vector	   is	   a	   virus.	   	   Scientists	   manipulate	   the	   genome	   of	  several	   different	   classes	   of	   viruses,	   including	   retroviruses,	   adenoviruses,	  adeno-­‐associated	   viruses,	   and	   herpes	   simplex	   viruses	   (21).	   	   Recently,	  scientists	   of	   Friedrich	  Miescher	   Institute	   for	   Biomedical	   Research	   (FMI)	   in	  Switzerland	  have	  introduced	  HR	  into	  the	  remaining,	  but	  nonfunctional,	  cone	  receptors	  in	  the	  macula	  of	  mice	  retinas	  afflicted	  with	  RP	  to	  restore	  vision	  via	  adeno-­‐associated	  viruses	  (11).	   	  The	  protein	  genetically	  targeted	  by	  the	  folks	  at	   FMI	  was	   an	   enhanced	  Natronomonas	   pharaonis	   halorhodopsin	   (eNpHR)	  because	   similar	   to	   healthy	   photoreceptors,	   this	   light-­‐activated	   chloride	  pumping	   protein	   hyperpolarizes	   in	   response	   to	   increases	   in	   light	   intensity	  (11).	   	  When	   testing	   treated	   light-­‐insensitive	   human	   retinas	   in	   vitro,	   it	   was	  discovered	  that	  the	  retinas	  with	  HR	  substituted	  in	  for	  the	  malfunctioning	  or	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degenerative	  native	  phototransduction	  cascade	  were	  capable	  of	   responding	  to	  light	  again	  after	  treatment,	  further	  validating	  the	  restoration	  of	  vision	  seen	  with	  mice	  retinas	  (11).	  	  	  Another	  modified	  gene	  therapy	  technique	  capable	  of	  restoring	  vision	  to	   those	   afflicted	   with	   AMD	   or	   RP	   is	   optogenetics.	   	   Optogenetics	   is	   a	   new	  technology	   that	   combines	   genetic	   and	   optical	   methods	   to	   control	   the	  behavior	  of	  cells.	  	  This	  method,	  developed	  by	  Karl	  Deisseroth	  and	  Ed	  Boyden,	  has	   been	   shown	   to	   control	   neurological	   events	   in	   the	   cell	   through	   the	  expression	   of	   microbial	   rhodopsins	   (22).	   	   Using	   recombinant	   adeno-­‐associated	   viral	   vectors	   (AAVs),	   the	   light-­‐activated	   protein,	  channelrhodopsin-­‐2	   (ChR2),	   has	   been	   expressed	   in	   retinal	  ON	  bipolar	   cells	  (13).	   	   ChR2	   is	   a	   gated	   algal	   cation	   channel	   activated	   by	   blue	   light.	   	   When	  activated,	  ChR2	  opens	  and	  allows	  an	  influx	  of	  Na+	  ions,	  similar	  to	  the	  influx	  that	   causes	   depolarization	   of	   nerve	   cells	   and	   leads	   to	   the	   firing	   of	   action	  potentials.	   	  Optogenetics	   is	   successful	  because	   this	   technology	   is	   capable	  of	  selectively	  targeting	  cells	  of	  interest.	   	  Halorhodopsin	  is	  often	  used	  to	  inhibit	  action	   potentials	   and	   ChR2	   is	   often	   used	   to	   trigger	   a	   neural	   response.	  	  Inhibition	  of	  bipolar	  cells	  would	  not	  restore	  sight	  to	  those	  afflicted	  with	  AMD	  or	  RP.	  	  This	  concept	  is	  supported	  by	  Busskamp	  et.	  al	  at	  FMI	  as	  they	  had	  noted	  the	   importance	   of	   restricting	   “the	   expression	   of	   eNpHR	   to	   photoreceptors	  only,	   because	   eNpHR	   	   in	   downstream	   retinal	   circuit	   elements,	   such	   as	  ON-­‐bipolar	  and	  ON-­‐ganglion	  cells,	  may	  inhibit	  the	  flow	  of	  information	  across	  the	  retina”	  (11).	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Distinct	  events	  in	  biological	  systems,	  including	  the	  visual	  system,	  can	  be	   targeted	   with	   precision	   when	   using	   optogenetics.	   	   This	   specificity	   of	  optogenetics	   enables	   higher	   resolution	   vision,	   in	   contrast	   to	   the	   electrical	  stimulation	   method,	   which	   activates	   all	   cell	   types	   without	   discrimination.	  	  While	   optogenetics	   offers	   vision	   with	   higher	   resolution	   and	   greater	  sensitivity,	   there	   are	   several	   disadvantages	   and	   drawbacks	   that	   must	   be	  considered.	   	   Components	   of	   optogenetics,	   namely	   ChR2	   and	   HR,	   require	   a	  high	   light	   intensity	   for	   activation.	   	   The	   laborious	   and	   difficult	   task	   of	  designing	   AAVs	   with	   specific	   promoter	   to	   target	   each	   cell	   type	   is	   also	  necessary	   for	   the	   successful	   implementation	   of	   optogenetics	   in	   treating	  retinal	  degenerative	  diseases.	   	  Lastly,	  an	  obvious	  barrier	  to	  overcome	  when	  considering	  the	  use	  of	  optogenetics	  and	  other	  types	  of	  gene	  therapy	  are	  the	  ethical	   and	   legislative	   concerns	   raised	   on	   the	   issues	   of	   genetic	   engineering	  (23).	   Despite	   major	   advances	   in	   gene	   therapy	   and	   optogenetics,	   retinal	  prostheses	   offer	   a	   viable	   option	   for	   vision	   restoration	   in	   patients	  with	   late	  stage	  AMD	  or	  RP.	  There	   are	   several	   alternative	   medical	   technologies	   currently	   being	  developed	  and	  acquiring	  acceptance	  with	  the	  Food	  and	  Drug	  Administration	  (FDA)	  through	  the	  FDA	  drug	  and	  biological	  approval	  process.	  	  In	  addition	  to	  the	   Birge	   Group’s	   protein-­‐based	   retinal	   implant,	   other	   medical	   device	  developments	  aimed	  towards	  treatment	  of	  AMD	  and	  RP	  include	  designs	  from	  the	   following	   companies:	   NanoRetina,	   Boston	   Retina	   Implant	   Project,	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Intelligent	  Medical	  Implants,	  Second	  Sight	  and	  the	  Department	  of	  Energy,	  and	  Optobionics.	  The	  FDA	  drug	  and	  biological	  approval	  process	  must	  be	  understood	  at	  a	  basic	  level	  in	  order	  to	  compare	  the	  feasibility	  of	  these	  retinal	  technologies.	  	  A	   medical	   device	   must	   clear	   five	   major	   stages	   in	   order	   to	   receive	   FDA	  approval.	   	   The	   first	   stage	   is	   one	   of	   intellectual	   property	   and	   laboratory	  research	  in	  which	  the	  concept	  is	  patented	  and	  initial	  research	  is	  completed.	  	  NanoRetina	  and	  Boston	  Retinal	   Implant	  Project	   are	   currently	   in	   this	  phase.	  	  The	  next	  phase	  in	  achieving	  FDA	  approval	  is	  pre-­‐clinical	  research.	  	  The	  Birge	  Group’s	  retinal	  prostheses	  and	  technologies	  of	  Intelligent	  Medical	  Implants	  is	  currently	  in	  this	  phase	  in	  which	  the	  device	  is	  being	  constructed	  and	  tested	  on	  animals.	   	   Obtaining	   scientific,	   ethical,	   and	   regulatory	   support	   for	   various	  institutional	  boards	  marks	  the	  third	  stage.	  	  The	  fourth	  stage	  of	  FDA	  approval	  process	  is	  that	  of	  clinical	  trials	  in	  which	  the	  medical	  technologies	  are	  tested	  in	   a	   controlled	   manner	   with	   human	   subjects	   in	   order	   to	   determine	   if	   the	  device	  is	  safe	  and	  effective.	  	  Lastly,	  devices	  must	  be	  authorized	  for	  Premarket	  Approval	   (PMA).	   	   Currently,	   Optobionics	   is	   at	   this	   stage	   of	   FDA	   approval.	  	  Understanding	  the	  stage	  in	  the	  FDA	  approval	  process	  a	  device	  is	  currently	  in	  is	  important	  when	  considering	  the	  relative	  timing	  of	  commercial	  availability	  of	   these	   alternative	   approaches	   for	   treatment	   of	   age-­‐related	   macular	  degeneration	  and	  retinitis	  pigmentosa.	  	  	  NanoRetina,	   Inc.	   is	   developing	   “an	   ultra	   small,	   easy	   to	   implant,	  artificial	  retina	  designed	  to	  restore	  sight”	  termed	  Bio-­‐Retina.	  	  Bio-­‐Retina	  is	  an	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implant	  composed	  of	  nanoelectrodes,	  electronic	  circuitry,	  photosensors,	  and	  IR	  recipient	  circuits,	  and	  a	  pair	  of	  eyeglasses	  that	  work	  together	  to	  translate	  the	   visual	   input	   into	   neural	   messages	   via	   a	   proprietary	   alogarithm	   (14).	  	  According	  to	  NanoRetina,	  Inc.,	  the	  Bio-­‐Retina	  implant	  is	  inserted	  with	  a	  thirty	  minute,	  minimally	   invasive	  surgery	  that	  requires	  only	   local	  anesthesia	  (15).	  	  The	   implant	   is	   attached	   to	   the	   retina	   and	   the	   electrodes	   of	   this	   implant	  protrude	   into	   several	   layers	   of	   the	   retina	   and	   interfaces	   with	   the	   bipolar	  neurons	   (14).	   	   Since	   neurons	   require	   electrical	   stimulation,	   specially	  designed,	   rechargeable	   eyeglasses	   supply	   an	   infrared	   beam	   to	   power	   the	  conversion	   of	   the	   eye’s	   optics	   to	   neural	   stimulation	   (15).	   	   As	   of	   now,	  NanoRetina,	   Inc.	   plans	   to	   attempt	   to	   start	   trials	   in	   2013,	   and	   if	   trials	   are	  successful,	   they	   state	   they	   hopefully	   their	  medical	   device	  will	   be	   a	   feasible	  option	  for	  those	  afflicted	  with	  AMD	  or	  RP	  in	  “two	  or	  three	  more	  years”	  (14).	  The	  Boston	  Retinal	  Implant	  Project,	  also	  in	  the	  initial	  phase	  of	  the	  FDA	  approval	   process,	   is	   a	   prototype	   with	   a	   subretinal	   microchip	   that	   has	  electrodes	  that	  directly	  activate	  optical	  nerves.	  	  According	  to	  Joseph	  Rizzo	  III,	  a	   principle	   researcher	   of	   the	   Boston	   Retinal	   Implant	   Project,	   this	   retinal	  implant	   includes	   both	   internal	   and	   external	   components	   and	  was	   designed	  with	   six	   principles	   in	  mind:	  minimal	   disruption	   of	   the	   anatomy	   of	   the	   eye;	  minimally	   invasive	   surgical	   methods	   for	   implanting	   the	   device;	   minimal	  sophistication	  of	  electronic	  components	  implanted	  into	  the	  eye	  and	  orbit;	  use	  of	   ultrathin	   flexible	   substrate	   that	   can	   bend	   to	   match	   the	   contour	   of	   the	  ocular	  tissues;	  use	  of	  wireless	  technology	  to	  provide	  a	  functional	  connection	  
	   16	  
between	  the	  external	  and	  the	  implanted	  device	  components;	  and,	  finally,	  use	  means	  to	  individually	  control	  and	  adjust	  the	  stimulation	  parameters	  to	  each	  electrode	  based	  on	  patient	  feedback	  (16).	  	  The	  Boston	  Retinal	  Implant	  device	  consists	  of	  a	  subretinal	  electrode	  array	  with	  over	  200	  individually	  controlled	  stimulating	   electrodes,	   and	   the	   rest	   of	   the	   device	   is	   outside	   of	   the	   eye,	  minimizing	  potential	  bio-­‐compatibility	  problems	  (16).	  	  Special	  glasses	  with	  a	  small	  camera	  and	  primary	  radio	  frequency	  coil	  around	  the	  rim	  must	  be	  worn	  to	   collect	   visual	   images	   and	  wirelessly	   transmit	   power	   and	   a	   signal	   to	   the	  radio	  frequency	  coil	  that	  is	  sutured	  around	  the	  limbus,	  or	  outside	  of	  the	  iris	  (16).	  	  The	  signal	  is	  then	  propagated	  from	  the	  radio	  frequency	  coil	  around	  the	  limbus	  to	  a	  hermetic	  integrated	  circuit,	  or	  “stimulating	  chip”	  that	  is	  titanium	  enclosed	   to	   increase	   the	   longevity	   of	   this	   retinal	   prosthesis,	   which	   in	   turn	  provides	  the	  electrical	  stimulation	  to	  the	  electrodes	  of	  the	  subretinal	  implant	  that	  then	  transfer	  the	  message	  to	  the	  optic	  nerves	  (16).	  	  The	  most	  prominent	  challenge	   with	   the	   Boston	   Retinal	   Implant	   Project	   is	   that	   with	   present	  technology,	   each	   of	   the	   200	   individually	   controlled	   stimulating	   electrodes	  requires	   a	   hard-­‐wired	   connection	   from	   the	   hermetic	   integrated	   circuit.	  	  Currently,	   these	  transistors	  are	  susceptible	  to	  destruction	  from	  exposure	  to	  water	  vapor	  and	  sodium	  ions	  that	  commonly	  occurs	  with	  the	  current	  device	  design	  (16).	   	  Ideally,	   looking	  to	  improve	  the	  quality	  and	  resolution	  of	  vision	  provided	   by	   this	   retinal	   implant	   in	   the	   future,	   the	   number	   of	   electrodes	  would	  need	  to	  be	  increased	  significantly.	  	  Presently,	  a	  miniaturized	  artificial	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device	  with	  15	  channels	  instead	  of	  200	  electrodes	  is	  being	  tested	  in	  Yucatan	  minipigs	  (16).	  Intelligent	   Medical	   Implants	   is	   a	   company	   based	   in	   Germany	   and	  Switzerland	   that	   has	   designed	   a	   device	   referred	   to	   as	   the	   Learning	   Retinal	  Implant.	  	  At	  this	  point,	  the	  Birge	  Group’s	  protein-­‐based	  retinal	  prosthesis	  and	  the	   Intelligent	   Retinal	   Implant	   system	   are	   both	   in	   the	   pre-­‐clinical	   research	  phase	   of	   the	   FDA	   approval	   process.	   	   The	   Learning	   Retinal	   Implant	   is	   an	  epiretinal	  device	  that	  was	  developed	  based	  on	  “the	  transformation	  of	  image	  signals	  from	  an	  extraocular	  camera	  into	  sequences	  of	  current	  pulses	  applied	  by	   implanted	   microelectrodes”	   (17).	   	   In	   addition	   to	   an	   implanted	  microelectrode	  stimulator,	   there	  are	   two	  necessary	  external	  components	  of	  this	  retinal	  prosthesis;	  eyeglasses,	  termed	  the	  Visual	  Interface	  by	  Intelligent	  Medical	   Implants,	   and	   the	  Pocket	  Processor.	   	  The	  digital	   camera	   integrated	  into	  the	  eyeglasses	  of	   the	  Visual	   Interface	  records	  visual	   information	  and	   is	  connected	  to	  the	  Pocket	  Processor	  via	  a	  cable.	  	  The	  Pocket	  Processor,	  which	  also	   supplies	   energy	   for	   this	   entire	   implant	   system,	   then	   converts	   these	  visual	   recordings	   into	   data	   signals	   that	   are	   transmitted	   wirelessly	   to	   the	  epiretinal	   microelectrode	   stimulator	   via	   infrared	   (IR)	   transmissions	   and	   a	  high-­‐frequency	  alternating	  electromagnetic	  field	  generated	  by	  metal	  coils	  in	  the	  frame	  of	  the	  eyeglasses	  of	  the	  Visual	  Interface	  (17).	  	  The	  electromagnetic	  field	   is	   received	   by	   the	   high	   frequency	   coil	   sutured	   to	   the	   sclera,	   the	  extraocular	  component	  of	  this	  epiretinal	  implant,	  while	  the	  IR	  transmissions	  are	   received	   and	   translated	   from	  optical	   signals	   into	   electrical	   impulses	   by	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the	   IR	   receiver	   of	   this	   epiretinal	   device	   (17).	   Successful	   animal	   trials	   with	  Gottinger	   minipigs	   have	   been	   completed	   with	   a	   model	   implant	   that	   is	  composed	  of	  a	  polyimide	  circuit	  board	  with	  gold	  conducting	  paths	  and	  that	  consists	  of	  49	  electrodes	  (17).	  	  Presently,	  technologies	  are	  being	  fine	  tuned	  in	  terms	  of	  the	  design	  of	  the	  electrodes	  of	  the	  microcontact	  array,	  attempting	  to	  find	   an	   optimal	   electrode	   size	   that	   balances	   between	   charge	   applied	   and	  selectivity.	  	  Further	  studies	  are	  being	  completed	  to	  assess	  biocompatibility	  in	  terms	   of	   the	   acute	   toxicity,	   subchronic	   toxicity,	   genotoxicity,	   implantation,	  chronic,	  toxicity,	  and	  carcinogenicity	  in	  order	  to	  pursue	  FDA	  approval	  (17).	  Second	   Sight	   and	   the	   Department	   of	   Energy	   have	   also	   developed	   a	  retinal	   prosthesis	   referred	   to	   as	   Argus	   II	   that	   is	   aimed	   to	   partially	   restore	  vision	  to	  blind	  patients.	  	  Argus	  II	  is	  the	  most	  advanced	  implant	  device	  in	  the	  stages	  of	  FDA	  approval,	  and	  it	  is	  already	  approved	  for	  commercial	  use	  in	  the	  European	  Economic	  Area	  and	  in	  fact,	  on	  October	  29,	  2011,	  Argus	  II	  became	  the	   first	   successful	   commercially	   implanted	   retinal	   prosthesis	   (18).	  	  Currently	  in	  the	  late	  stages	  of	  clinical	  trials	  in	  the	  United	  States,	  Argus	  II	  is	  an	  epiretinal	   implant	   that	   consists	   of	   a	   light-­‐sensitive	  microphotodiode	   array,	  which	  is	  connected	  to	  an	  electronics	  case	  with	  an	  antenna	  that	  surrounds	  the	  eye	  ball.	   	  The	  antenna	  receives	  electrical	  signals	  that	  were	  converted	  in	  real	  time	   from	   visual	   images	   by	   external	   equipment	   of	   the	   retinal	   device.	   	   This	  epiretinal	   implant,	  which	  receives	  processed	  electrical	  signals	   for	  the	  visual	  images	  gathered	  by	  a	  camera	  on	  glasses	  via	  antenna,	  bypasses	  degenerative	  photoreceptors	   completely	   and	   directly	   stimulates	   functioning	   neural	   cells	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such	  as	  ganglion	  and	  bipolar	  cells	  to	  allow	  the	  brain	  to	  perceive	  patterns	  of	  light	  which	  are	  ultimately	  interpreted	  as	  vision	  (24,	  25).	  	  	  The	   first	   FDA	   approved	   ophthalmic	   prostheses	   is	   the	   Implantable	  Telescope	  Technology	  of	  VisionCare	  Ophthalmic	  Technologies.	   	   Implantable	  Telescope	   Technology	   improves	   the	   sight	   of	   patients	   diagnosed	   with	   end	  stage	  AMD,	  or	  bilateral	  advanced	  dry	  AMD	  by	  magnifying	  the	  image	  seen	  by	  central	   vision	   to	   approximately	   two	   and	   half	   times	   the	   normal	   size.	   	   This	  magnification	   allows	   the	   image	   to	   be	   projected	   on	   a	   larger	   region	   of	   the	  retina	  allowing	  the	  remaining	  healthy	  photoreceptor	  cells	  around	  degenerate	  cells	   in	   the	   macula	   to	   see	   the	   majority	   of	   the	   image	   (19).	   	   The	   Telescope	  Implant	  itself	  is	  about	  the	  size	  of	  a	  pencil	  eraser	  and	  is	  implanted	  into	  the	  eye	  after	   the	   removal	   of	   the	  natural	   lens	   and	   cataracts	   to	  help	   improve	   central	  vision.	   	   Patients	   with	   the	   Telescope	   Implant	   wear	   normal	   eyeglasses	   to	  provide	  proper	  focus	  when	  viewing	  objects	  close	  up	  and	  far	  away.	  	  One	  eye,	  without	  the	  implant,	  is	  used	  for	  peripheral	  vision,	  and	  the	  other	  eye,	  with	  the	  Telescope	  Implant	  is	  used	  for	  detailed	  central	  vision	  (19).	  Another	  alternative	  device	  technology	  is	  currently	  in	  the	  clinical	  trial	  phase	   of	   FDA	   approval.	   	   Optobionics	   has	   developed	   an	   implant	   device	  deemed	  Artificial	  Silicon	  Retina	  (ASR)	  microchip.	  	  ASR	  is	  extremely	  tiny	  with	  only	   a	   diameter	   of	   2	   mm	   and	   a	   thickness	   of	   25	   μm	   (20).	   	   This	   subretinal	  implant	  is	  one-­‐tenth	  the	  size	  of	  a	  penny	  and	  thinner	  than	  a	  strand	  of	  human	  hair	   and	   is	   classified	   as	   a	   semiconductor	   microphotodiode	   array	   chip.	  	  Microphotodiodes	  are	  microscopic	  solar	  cells	  each	  with	   its	  own	  stimulating	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electrode,	  and	  ASR	  has	  approximately	  5000	  of	   these	  microphotodiodes	  that	  are	   powered	   solely	   by	   incident	   light	   and	   intended	   to	   “alter	   the	  membrane	  potential	   on	   contacting	   retinal	   neurons	   and	   to	   stimulate	   how	   light	   would	  normally	   activate	   these	   cells	   to	   form	   retinotopic	   visual	   images	   (20).	   	   After	  successfully	   implanting	   the	   ASR	   disc	   in	   the	   cat,	   pig,	   and	   rat	   models,	  Optobionics	  has	  begun	  clinical	  trials	  with	  humans.	  	  To	  date,	  the	  ASR	  chip	  has	  been	   implanted	   in	   42	   patients	   with	   RP,	   and	   not	   only	   have	   visual	  improvements	   been	   stabilized,	   but	   also,	   there	   were	   unexpected	  improvements	   in	   retinal	   areas	   distant	   from	   the	   implant	   (20).	   	   This	  “neurotrophic	  rescue	  effect”	  has	  resulted	  in	  a	  degree	  of	  vision	  recovery	  that	  has	   included	  “visual	  acuity,	  contrast	  and	  color	  perception,	  and	  expansion	  of	  the	  visual	   field”	   (20).	   	  One	  major	  drawback	  of	  ASR,	   that	   the	  ASR	  microchip	  relies	  on	  the	  presence	  of	  some	  viable	  retina	  for	  stimulation	  to	  occur,	  is	  also	  a	  concern	  of	  the	  Birge	  Group’s	  protein-­‐based	  retinal	  prosthesis.	  	  
1.5. Design	  of	  Birge	  Group	  Artificial	  Retina	  The	   artificial	   retina	   proposed	   by	   the	   Birge	   Group	   involves	   the	  implementation	  of	   a	  multilayered	   ion-­‐patch	   layered	   for	   the	   conversion	  of	   a	  light-­‐activated	  protein	  to	  convert	  light	  stimulation	  into	  an	  electrical	  gradient	  that	  excites	  the	  retinal	  bipolar	  cells	  (Figure	  6).	  	  In	  the	  Birge	  Artificial	  Retina,	  BR	  and	  HR	  will	  be	  used	  to	  stimulate	  the	  retinal	  bipolar	  and	  ganglion	  cells	  via	  an	  ion	  gradient.	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Figure	   6:	   Protein-­‐Based	   Chloride	   Ion-­‐Patch	   Implant.	   	   The	   layered	   protein-­‐based	  patch	   implant	   (in	  purple)	  uses	   light	  activated	  proteins	   to	  replace	   the	  function	   of	   damaged	   photoreceptor	   cells.	   	   The	   Birge	   Group	   artificial	   retina	  implant	   is	   intended	  to	  stimulate	  the	  retina	  of	  patients	  with	  AMD	  and	  RP	  by	  generating	  an	  ion	  gradient,	  which	  will	  activate	  the	  bipolar	  and	  ganglion	  cells.	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Halorhodopsin	  is	  a	  transmembrane	  retinylidene	  protein	  that	  naturally	  pumps	   a	   chloride	   ion	   in	   response	   to	   light	   activation.	   	   Bacteriorhodopsin,	   a	  similar	  protein	  to	  HR	  that	  instead	  natively	  pumps	  a	  proton,	  can	  be	  altered	  via	  site-­‐directed	  mutagenesis	  into	  a	  chloride	  ion	  pump,	  which	  functions	  similarly	  to	  HR.	   	  The	  retinylidene	  protein	  of	  choice	  will	  be	   layered	  and	  oriented	  on	  a	  small	   piece	   of	   Dacron®,	   a	   synthetic	   fabric	   that	   is	   chemically	   inert	   in	  biological	  systems,	  such	  as	  the	  retina	  (26).	  The	   chloride	   ion	   gradient-­‐inducing	   protein-­‐based	   artificial	   retina	  developed	  by	  the	  Birge	  Group	  does	  not	  require	  any	  external	  equipment	  such	  as	   a	   camera	   or	   power	   source	   as	   necessary	   for	   other	   retinal	   implants.	   	   The	  Birge	   Group	   retinal	   prostheses	   implements	   a	   subretinal	   design	   in	   order	   to	  create	  an	  ion	  gradient	  close	  enough	  in	  proximity	  to	  bipolar	  cells	  to	  stimulate	  a	  response	  (Figure	  7).	  	  The	  artificial	  implant	  will	  solely	  consist	  of	  the	  protein-­‐based	  chloride	  ion-­‐patch.	  	  Implementation	  of	  retinylidene	  proteins	  as	  a	  light-­‐induced	  ions	  requires	  that	  the	  protein	  be	  uniformly	  oriented	  over	  the	  entire	  multi-­‐layered	  patch.	   	  The	  protein	  will	  be	  aligned	  via	   the	  electrostatic	   layer-­‐by-­‐layer	  method	   through	  an	  automated	  dipper	  system,	  allowing	   for	  control	  of	  the	  film	  thickness	  and	  yielding	  the	  most	  uniformly	  oriented	  protein	  layers	  with	   a	   positively	   charged	   polymer	   between	   each	   protein	   layer	   (27).	   	   The	  longevity	   of	   this	   protein-­‐based	   chloride	   ion-­‐patch	   will	   depend	   on	  whether	  HR	   or	   BR	   is	   the	   protein	   basis;	   Bacteriorhodopsin	   has	   a	   stable	   bench	   top	  lifetime	  of	  seven	  years	  whereas	  the	  lifetime	  of	  Halorhodopsin	  is	  about	  a	  year	  at	  4°C	  (28,	  29)	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Figure	   7:	   Schematic	   Diagram	   of	   Protein-­‐Based	   Subretinal	   Implant.	   	   In	   this	  design,	  light	  enters	  through	  the	  nerve	  fiber	  layer	  and	  is	  focused	  on	  the	  retina,	  stimulating	  the	  oriented,	  multilayered	  thin	  films	  of	  HR	  or	  BR	  (in	  purple).	  	  The	  protein-­‐based	   patch	   then	   generates	   a	   photochemically	   induced	  unidirectional	  chloride	  ion	  gradient	  to	  stimulate	  adjacent	  bipolar	  cells	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1.6. Comparison	  of	  Halorhodopsin	  and	  Bacteriorhodopsin	   for	  Use	   in	  
an	  Ion	  Gradient-­‐Inducing	  Protein-­‐Based	  Artificial	  Retina	  The	   seven	   transmembrane	   retinal	   protein	   Halorhodopsin	   (HR)	   uses	  the	   energy	   of	   green	   light	   to	   act	   as	   a	   chloride	   ion	   pump	   (Figure	   8).	  	  Halorhodopsin,	  found	  in	  Halobacterium	  salinarum,	  functions	  as	  a	  light-­‐driven	  anion	  pump	  with	  an	  absorption	  maxima	  at	  578	  nm.	  	  A	  chloride	  ion	  is	  pumped	  from	  the	  extracellular	  matrix	  into	  the	  cytoplasm,	  forming	  an	  ion	  gradient	  by	  HR	   (30,	   31).	   	   Bacteriorhodopsin,	   also	   a	   seven	   transmembrane	   protein,	  functions	  slightly	  differently	  in	  that	  it	  is	  a	  light-­‐activated	  hydrogen	  ion	  pump	  (32)	   (Figure	  8).	   	   Structurally,	  HR	   and	  BR	   are	   considered	   very	   similar.	   	   The	  primary	   amino	   acid	   structures	   of	  HR	   and	  BR	   are	   actually	   homologous	   (33)	  (Figure	  9).	   	  There	  are	   just	  a	   few	  key	  conspicuous	  residual	  changes	   that	  are	  representative	   of	   the	   different	   functional	   groups	   and	   charges	   needed	   to	  transport	  a	  chloride	  ion	  instead	  of	  a	  proton.	  	  A	  specific	  example	  can	  be	  found	  at	   the	   eighty-­‐fifth	   amino	   acid	   residue.	   	   In	  BR,	   the	   eighty-­‐fifth	   amino	   acid	   is	  aspartic	  acid,	  while	  in	  HR	  the	  eighty-­‐fifth	  amino	  acid	  is	  threonine	  (33).	  	  Even	  though	   HR	   is	   a	   naturally	   occurring	   chloride	   ion-­‐pump,	   BR	   is	   the	   ultimate	  protein	   of	   interest	   for	   use	   in	   an	   artificial	   retina	   because	   of	   its	   inherent	  biological	  stability	  and	  ultra-­‐fast	  photovoltaic	  response	  (capability	  of	  quickly	  converting	  light	  energy	  into	  an	  electrical	  signal)	  (28).	  	  This	  research	  worked	  towards	  exploring	  and	  optimizing	  the	  methods	  to	   express	   and	   purify	   Halorhodopsin	   in	   order	   to	   create	   and	   study	   the	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efficiency	  of	  a	  light-­‐induced	  chloride	  gradient	  from	  a	  protein-­‐based	  artificial	  retina.	  	  	  
	  	  
Figure	  8:	  Comparison	  of	  Secondary	  Structure	  of	  HR	  and	  BR.	  	  Both	  HR	  (Top)	  and	   BR	   (Bottom)	   are	   integral	   seven	   transmembrane	   alpha-­‐helical	   proteins	  with	  a	  retinal	  chromophore.	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Figure	   9:	   Comparison	   of	   key	   amino	   acid	   residues	   in	   HR	   and	   BR.	   	   In	   this	  figure,	   modified	   from	   Essen	   (30),	   the	   key	   amino	   acids	   responsible	   for	   the	  functionality	   of	   both	   HR	   (left)	   and	   BR	   (right)	   are	   noted.	   	   Halorhodopsin	  pumps	   a	   chloride	   ion	   from	   the	   extracellular	   to	   the	   cytoplasmic	   surface.	   	   In	  contrast,	   BR	   pumps	   a	   proton	   from	   the	   cytoplasmic	   to	   the	   extracellular	  surface.	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2. Materials	  and	  Methods	  
2.1.	  	   Expression	  of	  Halorhodopsin	  Halorhodopsin	   (HR)	   was	   purified	   and	   grown	   from	   a	   slant	   obtained	  from	  John	  Spudich	  at	  the	  Center	  for	  Membrane	  Biology,	  at	  the	  University	  of	  Texas	  Medical	  School.	   	  The	  expression	  of	  HR	  was	  measured	  as	  a	  function	  of	  the	  optical	  density	  (OD)	  at	  660nm	  every	  ten	  minutes	  in	  the	  UV	  Spectrometer.	  	  The	  data	  recorded	  was	  then	  used	  to	  create	  a	  growth	  curve	  for	  HR.	  	  
2.2.	  	   Growth	  of	  Stock	  Culture	  of	  Halorhodopsin	  for	  Plating	  	   Halorhodopsin	  was	  scaled	  up	  from	  freezedown	  by	  inoculating	  5	  mL	  of	  LB	   media	   containing	   12	   uL	   of	   50	   ug/mL	   ampicillin	   with	   100	   uL	   of	  freezedown	   culture.	   	   The	   cultures	  were	   allowed	   to	   shake	   overnight	   at	   200	  rpm	  at	  37°C.	  	  Dilutions	  of	  HR	  (1:50,	  1:100,	  1:500,	  and	  1:1000)	  were	  prepared	  for	  plating	  onto	  LB-­‐ampicillin	  plates.	  	  
2.3.	  	   Inoculation	  from	  Plates	  	   Colonies	   were	   isolated	   from	   the	   LB-­‐amp	   and	   placed	   in	   5	   mL	   of	   LB	  broth	  containing	  50	  ug/mL	  ampicillin.	  	  After	  growing	  overnight	  in	  the	  shaker,	  a	  1:100	  dilution	  was	  taken	  from	  each	  sample	  and	  placed	  into	  fresh	  LB	  with	  ampicillin	  and	  allowed	  to	  shake	  at	  37°C	  and	  200	  rpm	  for	  three	  hours.	  	  	  	  
2.4.	  	   Expression	  and	  Purification	  of	  Halorhodopsin	  
Escherichia	  coli	  (E.	  coli)	  BL21(DE3)	  cells	  transformed	  with	  pET21-­‐HR	  
	   28	  
were	  grown	  at	  37°C	  in	  LB	  medium	  supplemented	  with	  50	  ug/mL	  ampicillin.	  	  At	  an	  OD660	  of	  0.35-­‐0.40,	  1	  mM	  IPTG	  and	  1	  mM	  all-­‐trans	  retinal	  or	  5	  mM	  all-­‐
trans	   retinal	  were	  added.	   	  After	  an	   induction	  period	  of	   three	  hours	  at	  30°C,	  the	  cells	  were	  then	  harvested	  by	  centrifugation	   in	   JLA-­‐17	   for	  10	  minutes	  at	  5,000	  rpm.	  	  Harvested	  cells	  were	  washed	  and	  resuspended	  in	  a	  HEPES	  buffer	  (50	  mM	  HEPES,	  500	  mM	  NaCl,	  pH	  7.0)	  and	  finally	  broken	  up	  with	  a	  sonicator	  (Fisher	  Scientific	  550	  Sonic	  Dismembrator).	  	  Sonicated	  cells	  were	  centrifuged	  in	   JA	   17	   for	   15	   minutes	   at	   6,000	   rpm	   and	   to	   collect	   the	   supernatant.	  	  Membranes	  were	  sedimented	  at	  35,000	  rpm	  for	  two	  hours	  at	  4°C	  (Beckman	  UltraCentrifuge)	  and	  solubilized	  in	  buffer	  S	  (50	  mM	  HEPES,	  500	  mM	  NaCl,	  5	  mM	   imidazole,	   pH	   7.0)	   	   10%	   w/v	   detergent	   (n-­‐Dodecyl-­‐β-­‐D-­‐maltoside	  [DDM])	  was	  added	  to	  sample.	  	  Pellet	  was	  solubilized	  with	  a	  sonicator	  (Fisher	  Scientific	  550	  Sonic	  Dismembrator)	  and	  then	  centrifuged	  at	  35,000	  rpm,	  4°C	  for	  20	  minutes	  (Beckman	  Coulter	  OptimaTM	  MAX-­‐E	  Ultracentrifuge,	  TLA55).	  	  Sonication	   and	   centrifugation	   repeated	   until	   no	   strong	   color	   from	   HR	  remained.	  	  Supernatant	  of	  the	  solubilized	  membranes	  was	  combined	  Ni-­‐NTA	  agarose	   his-­‐binding	   resin	   (QIAGEN).	   	   The	   Ni-­‐NTA	   resin	   was	   filled	   into	   a	  chromatography	   column	   and	   washed	   with	   buffer	   W	   (0.1%	   DDM,	   50	   mM	  HEPES,	   500	  mM	  NaCl,	   pH	   7.0)	   with	   an	   increasing	   imidazole	   concentration	  (≤30	   mM)	   to	   remove	   unspecifically	   bound	   proteins.	   	   Subsequently,	   the	  histidine	  tagged	  HR	  was	  eluted	  in	  buffer	  F	  (0.02%	  DDM,	  50	  mM	  HEPES,	  500	  mM	  NaCl,	  250	  mM	  imidazole,	  pH	  7.0).	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2.5.	  	   Halorhodopsin	  Characterization	  
	   Characterization	   of	   induced	   HR	   fractions	   was	   accomplished	   using	  sodium	   dodecyl	   sulfate	   polyacrylamide	   gel	   electrophoresis	   (SDS-­‐PAGE)	  analysis.	   	  Protein	  samples	   from	  various	   time	  points	  and	  dilutions	  were	   run	  on	   Criterion	   Precast	   Gels,	   12.5%	   TRIS-­‐HCL,	   1.0	   mm,	   18	   well	   comb,	   30	   uL	  (BioRad,	   MA)	   and	   Coomassie	   stained.	   	   As	   a	   standard,	   protein	   molecular	  weight	   marker	   (Invitrogen,	   NY)	   and	   a	   sample	   of	   wild	   type	   BR	   were	   also	  loaded.	   	   SDS-­‐PAGE	  gels	  were	   analyzed	   for	   a	  band	  at	  27	  kDa,	   the	  molecular	  weight	  of	  HR.	   	  Ultraviolet	   –visible	   spectroscopy	  was	  used	   to	  determine	   the	  absorption	  maxima	  (Cary	  50	  Scan	  UV-­‐Visible	  Spectrophotometer).	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3. Results	  and	  Discussion	  
3.1.	  	   Growth	  Curve	  of	  Halorhodopsin	  	   HR	  growth	  was	  monitored	  at	  660	  nm	  for	  three	  hours	  after	  induction	  with	  IPTG	  and	  all-­‐trans	  retinal.	  	  OD660	  as	  listed	  in	  Table	  1	  below	  were	  used	  to	  construct	   a	   growth	   curve	   for	   HR.	   	   Analysis	   of	   the	   generated	   growth	   curve	  (Graph	   1)	   determined	   that	   the	   optimal	   OD660	   to	   induce	  with	   IPTG	   and	   all-­‐
trans	  retinal	  was	  between	  0.35	  and	  0.40.	  	  
Table	  1:	  OD660	  of	  HR	  for	  Three	  Hours	  at	  10-­‐Minute	  Intervals.	  Time	  	  (Minutes)	   Sample	  1	  OD	  at	  660	  nm	   Sample	  2	  	  OD	  at	  660	  nm	  0	   0.0240	   0.0189	  10	   0.0169	   0.0190	  20	   0.0336	   0.0257	  30	   0.0371	   0.0364	  40	   0.0450	   0.0547	  50	   0.0671	   0.0715	  60	   0.0940	   0.0939	  70	   0.1344	   0.1441	  80	   0.2006	   0.1970	  90	   0.2503	   0.2631	  100	   0.3285	   0.3564	  110	   0.4725	   0.4608	  120	   0.5081	   0.5197	  130	   0.6327	   0.6426	  140	   0.7896	   0.7837	  150	   0.9251	   0.9405	  160	   1.0622	   1.0791	  170	   1.1741	   1.1805	  180	   1.2439	   1.2791	  190	   1.3298	   1.3536	  200	   1.4035	   1.4182	  210	   1.4703	   1.4749	  220	   1.5133	   1.5156	  230	   1.5548	   1.5843	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Graph	  1:	  Growth	  Curve	  of	  Halorhodopsin.	  
	  
	  
3.2.	  	   SDS-­‐PAGE	  Induction	  Assay	  	  	   Induced	   HR	   samples	   were	   characterized	   by	   SDS-­‐PAGE	   and	   the	  absorption	  maxima	  were	  measured	   to	   confirm	   expression.	   	   The	   SDS-­‐PAGE	  gels	   showed	   a	   band	   at	   27	   kDA,	   the	   molecular	   mass	   of	   HR	   affirming	  expression	   (Figure	   10).	   	   Induced	   HR	   samples	   were	   found	   to	   have	   an	  absorbance	   at	   575.9	   nm	   (data	   not	   shown),	   similar	   to	   the	   accepted	  absorbance	  of	  HR	  is	  578	  nm,	  and	  identical	  to	  experimental	  absorbance	  of	  HR	  (34).	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Figure	   10:	   SDS-­‐PAGE	   Analysis	   of	   HR.	   	   Assessment	   of	   both	   gels	   shows	   an	  increase	   in	   intensity	   of	   the	  HR	   band	   (at	  molecular	  weight	   27	   kDa)	   as	   time	  increases	  from	  0	  to	  180	  minutes	  for	  induced	  samples.	  	  The	  top	  gel	  (A)	  shows	  comparison	  between	  a	  sample	  induced	  with	  1	  mM	  IPTG	  and	  5	  mM	  all-­‐trans	  retinal	  (left)	  and	  a	  control	  sample	  (right).	  	  The	  arrow	  indicates	  the	  presence	  of	  a	  27	  kDa	  band	  in	  the	  HR	  sample,	  and	  the	  absence	  of	  a	  band	  at	  27	  kDa	  in	  the	  control	   sample.	   	  The	  bottom	  gel	   (B)	   consists	  of	   sample	   induced	  with	  1	  mM	  IPTG	   and	   1	   mM	   all-­‐trans	   retinal	   and	   a	   1:10	   dilution	   of	   that	   sample.	   	   The	  intensity	  of	  the	  27	  kDa	  band	  increases,	  as	  indicated	  by	  the	  arrows,	  from	  time	  0	   to	   180	   minutes	   after	   induction.	   	   Wells	   marked	   with	   an	   asterix	   (*)	  demonstrate	  the	  confirmed	  expression	  of	  HR.	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3.3.	  	   Purification	  of	  Halorhodopsin	  
	   Protein	   expression	   was	   carried	   out	   as	   described	   by	   Spudich	   et.	   al.	  (34).	  	  The	  histidine	  tagged	  proteins	  were	  not	  successfully	  extracted	  from	  the	  solubilized	   membrane	   faction	   by	   incubation	   with	   Ni-­‐NTA	   agarose.	   	   It	   was	  expected	   that	   after	   filtering	   and	  washing	   the	   resin	  with	   a	   step	   gradient	   of	  imidazole	  the	  bound	  HR	  would	  have	  eluted.	  	  For	  future	  work	  in	  purifying	  HR,	  alternative	  buffers,	  such	  as	  a	  Tris-­‐HCl	  buffer	  should	  be	  experimented	  with.	  	  	  	  
4. Conclusions	  Halorhodopsin	   was	   successfully	   expressed.	   	   It	   was	   determined	   that	  there	   was	   not	   a	   significant	   difference	   when	   inducing	   with	   1	   mM	   all-­‐trans	  retinal	   versus	   5	   mM	   all-­‐trans	   retinal.	   	   For	   future	   work,	   HR	   purification	  protocol	  needs	   to	  be	  optimized.	   	  Alternatives	   to	  protocol	   include	  modifying	  the	  buffer	  from	  a	  HEPES	  buffer	  to	  another	  buffer,	  such	  as	  one	  with	  Tris-­‐HCl	  as	   the	   basis.	   	   Solubilizing	   methods	   could	   also	   be	   altered	   to	   include	  homogenization	  in	  addition	  to	  sonication.	  	  After	  HR	  is	  successfully	  purified,	  a	  protein-­‐based	   patch	   with	   multiple	   oriented	   layers	   of	   HR	   should	   be	  assembled.	   	   Preliminary	   trials	   should	   then	   be	   carried	   out	   to	   compare	   the	  efficiency	   and	   stability	   of	   an	   artificial	   retina	   implant	   based	   on	   HR	   versus	  chloride	  ion	  pumping	  variants	  of	  BR.	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Appendix	  	  
	  
A:	  Media	  Preparation	  
	  
A.1.	  	  Luria	  Bertani	  (LB)	  broth	  (1L)	  	   10.0	  g	  tryptone	  5.0g	  yeast	  extract	  10.0g	  sodium	  chloride	  15.0g	  noble	  agar	  1L	  ddH2O	  	  	  
A.2.	  	  Luria	  Bertani	  (LB)	  –	  Ampicillin	  plates	  (1L)	  10.0	  g	  tryptone	  5.0g	  yeast	  extract	  10.0g	  sodium	  chloride	  15.0g	  noble	  agar	  1L	  ddH2O	  	  Adjust	  to	  pH	  7.2	  using	  5N	  NaOH	  Autoclave	  (Cycle	  3	  –	  Liquid)	  Cool	  before	  adding	  1mL	  ampicillin	  (50	  ug/mL),	  pour	  25mL	  media	  into	  petri	  dishes	  and	  allow	  to	  sit	  overnight	  to	  harden.	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A.3.	  	  Ampicillin	  (50mg/mL)	  (15	  mL)	  750	  mg	  of	  ampicillin	  	   15	  mL	  ddH2O	  	  Filter	  sterilize	  1	  mL	  aliquots	  with	  millex-­‐HA	  0.45	  um	  Millipore;	  store	  at	  -­‐20°C.	  	  	  
A.4.	  	  IPTG	  Stock	  Solution	  (1M)	  (10	  mL)	  2.38831	  g	  IPTG	  10	  mL	  of	  RNase	  free	  H2O	  
	  IPTG:	   	  IPTG	  
	  Filter	  sterilize	  1	  M	  IPTG	  stock	  solution	  in	  0.45	  um	  filter.	  Aliquot	  1	  M	  IPTG	  into	  1	  mL	  microfuge	  for	  future	  use.	  	  Store	  at	  -­‐20°C.	  
	  
	  
A.5.	  	  1	  mM	  all-­‐trans	  retinal	  	  
	   50	  uL	  0.1	  M	  all-­‐trans	  retinal	  	   5	  mL	  ethanol	  	   	  	   	  V1=0.05mL=50uL	  	  	  	  	  	  
238.13 gmol ×
1 mol
1 L ×0.01 L = 2.38831g
0.1 M =100 mM =100,000 µM
C1 ⋅V1 =C2 ⋅V2
100,000µM( ) ⋅V1 = 1000µM( ) ⋅ 5mLethanol( )
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A.6.	  	  Destain	  Solution	  (2L)	  175	  mL	  methanol	  1625	  mL	  H2O	  200	  mL	  acetic	  acid	  	  Prepared	  over	  ice	  and	  in	  hood,	  slowing	  adding	  acid	  to	  water.	  	  	  
A.7.	  	  1	  M	  Tris-­‐HCl	  pH	  6.8	  78.8g	  of	  Tris	  HCl	  	  0.5	  L	  of	  ddH2O	  	  	  pH	  to	  6.8	  using	  NaOH	  	  	  
A.	  8.	  	  4x	  Sample	  Buffer	  (10	  mL)	  	   4	  mL	  100%	  glycerol	  2.4	  mL	  1	  M	  Tris	  HCl	  pH	  6.8	  0.8	  g	  Sodium	  dodecyl	  sulfate	  (SDS)	  4	  mg	  bromophenol	  blue	  500	  uL	  2-­‐mercaptoethanol	  3.1	  mL	  ddH2O	  	  	  
A.9	  	  HEPES	  Buffer	  -­‐	  50	  mM	  HEPES	  Buffer,	  500	  mM	  NaCl,	  pH	  7.0	  (1L)	  	  	   14.38	  g	  HEPES	  7.93	  mL	  5N	  NaOH	  29.22	  g	  NaCl	  1	  L	  dH2O	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A.10	  	  50	  mM	  HEPES	  Buffer,	  500	  mM	  NaCl,	  5	  mM	  imidazole,	  pH	  7.0	  (0.5L)	  
	   500	  mL	  HEPES	  Buffer	  (A.9)	  0.1702	  g	  imidazole	  	   	  
A.11	  	  1.0%	  DDM,	  50	  mM	  HEPES	  Buffer,	  500	  mM	  NaCl,	  5	  mM	  imidazole,	  	  
	  	  	  	  	  	  	  	  	  	  	  	  pH	  7.0	  	  (80	  mL)	  
	   80	  mL	  HEPES	  Buffer	  (A.9)	  0.027	  g	  imidazole	  0.8	  g	  n-­‐Dodecyl-­‐β-­‐D-­‐maltoside	  (DDM)	  	  	  	  
Appendix	  B:	  Halorhodopsin	  Growth	  and	  Expression	  	  
B.1	  	  Halorhodopsin	  Expression	  1. 5	  mL	  LB	  media	  2. 12	  uL	  of	  50	  mg/mL	  ampicillin	  	  3. Add	  50	  uL	  of	  HR	  culture	  a. Freezedown	  stock	  	  b. Active	  culture	  4. Place	  tubes	  in	  shaker	  at	  200	  rpm	  at	  37°C	  overnight	  (~8-­‐10	  hrs.)	  5. Pass	  the	  freezedown	  culture	  into	  new,	  fresh	  LB	  media	  contain	  12	  uL	  of	  50	  mg/mL	  ampicillin	  a. 5	  mL	  of	  fresh	  LB	  using	  aseptic	  technique	  into	  autoclaved	  test	  tube	  b. 12	  uL	  of	  stock	  amp	  into	  each	  c. 50	  uL	  of	  previous	  culture;	  place	  in	  shaker	  37°C	  6. After	  approximately	  2	  or	  2.5	  hours,	  remove	  tubes	  from	  37°C	  shaker	  7. Create	  3	  dilutions	  of	  culture	  in	  fresh	  LB	  a. 1:100	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b. 1:500	  c. 1:1,000.	  8. Warm	  LB-­‐Amp	  plates	  in	  incubator	  9. After	  a	  half	  hour,	  of	  warming,	  remove	  the	  plates	  and	  plate	  50	  uL	  of	  each	  dilution	  onto	  separate	  LB-­‐ampicillin	  plates.	  	  	  a. Be	  sure	  to	  evenly	  spread	  50	  uL	  dilution	  across	  the	  whole	  plate	  with	  a	  plate	  spreader	  10. Place	  plates	  in	  37°C	  incubator	  for	  6-­‐8	  hours	  until	  colonies	  grow	  a. Note:	  Monitor	  growth	  to	  avoid	  overgrowing	  11. Remove	  plates	  and	  store	  upside	  down	  in	  4°C	  up	  	  	  	  
B.2	  	  Inoculation	  of	  HR	  from	  LB-­‐ampicillin	  plates	  for	  growth	  1. Add	  3	  mL	  LB	  into	  tube	  using	  aseptic	  technique	  2. Add	  12	  uL	  of	  amp	  to	  each	  tube	  3. Take	  one	  healthy	  colony	  (large	  and	  isolated)	  from	  the	  plate	  with	  inoculation	  tip	  or	  pipet	  tip	  into	  autoclaved	  test	  tubes	  	  	  
B.3	  	  Halorhodopsin	  Freezedown	  Preparation	  1. Combine	  500	  uL	  of	  sample	  and	  500	  uL	  of	  80%	  glycerol	  	  
	  
	  
B.4	  	  Induction	  of	  Halorhodopsin	  1. Samples	  were	  passed	  into	  fresh	  LB	  and	  amp	  and	  allowed	  to	  shake	  for	  approximately	  3	  hours	  at	  37°C,	  200	  rpm	  2. Induce	  cultures	  to	  1	  mM	  IPTG	  and	  1	  mM	  all-­‐trans	  retinal	  OR	  to	  1	  mM	  IPTG	  and	  5	  mM	  all-­‐trans	  retinal.	  3. Incubate	  in	  shaker	  at	  30°C,	  200	  rpm	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B.5	  	  Preparation	  for	  SDS-­‐PAGE	  Induction	  Assay	  1. Induce	  samples	  to	  1	  mM	  IPTG	  and	  either	  1	  mM	  all-­‐trans	  retinal	  or	  5	  mM	  all-­‐trans	  retinal	  2. Take	  500	  uL	  from	  sample	  every	  30	  minutes	  after	  induction	  starting	  at	  time	  0	  (time	  of	  induction).	  	  Keep	  samples	  over	  ice.	  3. Determine	  the	  OD660	  at	  each	  time	  point.	  4. Add	  200	  uL	  dH2O	  and	  200	  uL	  10%	  TCA	  (to	  lyse	  cells)	  to	  each	  400	  uL	  portion	  of	  sample.	  5. Pellet	  in	  centrifuge	  at	  12,000rpm	  for	  10	  minutes.	  	  Aspirate/remove	  all	  TCA	  waste.	  6. Resuspend	  pellet	  in	  25	  uL	  of	  4x	  Sample	  Buffer	  and	  75	  uL	  RNAse-­‐free	  water.	  7. Insert	  25	  uL	  samples	  into	  each	  well.	  	  8. Run	  gels	  at	  200	  V	  for	  approximately	  an	  hour	  9. Place	  gels	  in	  coomasie	  stain	  and	  gently	  shake	  overnight.	  10. Soak	  gels	  in	  destain.	  11. Transfer	  gels	  to	  water;	  proceed	  to	  dry	  gels	  if	  desired.	  
	  
	  
B.6	  	  Purification	  of	  His	  tagged	  HR	  1. Pellet	  the	  E.	  coli	  cells	  by	  centrifugation	  at	  	  5,000	  rpm	  for	  15	  minutes.	  2. Resuspend	  pellets	  in	  50	  mM	  HEPES,	  500	  mM	  NaCl,	  pH	  7.0	  buffer.	  3. Disrupt	  the	  cells	  with	  a	  sonicator.	  4. Sonicated	  samples	  were	  collected	  by	  low-­‐speed	  centrifugation	  at	  6,000	  rpm	  for	  15	  minutes.	  5. Supernatant	  was	  collected	  and	  spun	  at	  35,000	  rpm	  for	  two	  hours.	  6. Pellet	  was	  resuspended	  in	  50	  mM	  HEPES,	  500	  mM	  NaCl,	  5	  mM	  imidazole,	  pH	  7.	  7. 10%	  w/v	  detergent	  (n-­‐Dodecyl-­‐β-­‐D-­‐maltoside	  [DDM])	  was	  added	  to	  resuspended	  pellet.	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8. Sample	  was	  solubilized	  using	  a	  sonicator	  and	  then	  ultracentrifuged	  at	  35,000	  rpm	  for	  20	  minutes.	  	  This	  step	  was	  repeated	  until	  no	  strong	  color	  due	  to	  HR	  remained	  in	  pellet.	  9. Solubilized	  fraction	  was	  combined	  with	  QIAGEN	  Ni-­‐NTA	  agarose	  his-­‐binding	  resin	  with	  an	  anticipated	  binding	  efficiency	  of	  about	  3.5	  mg/mL	  (protein/resin).	  10. Resin	  was	  packed	  in	  column	  and	  washed	  with	  4x	  bed-­‐volume	  of	  1.0%	  DDM,	  50	  mM	  HEPES,	  500	  mM	  NaCl,	  5	  mM	  imidazole,	  pH	  7.0.	  11. Resin	  was	  washed	  with	  2x	  bed-­‐volume	  of	  0.1%	  DDM,	  50	  mM	  HEPES,	  500	  mM	  NaCl,	  5	  mM	  imidazole,	  pH	  7.0.	  12. Resin	  was	  washed	  with	  more	  than	  4x	  bed-­‐volume	  of	  0.02%	  DDM,	  50	  mM	  HEPES,	  500	  mM	  NaCl,	  20	  mM	  imidazole,	  pH	  7.0.	  13. Sample	  was	  eluted	  with	  10	  mL	  0.02%	  DDM,	  50	  mM	  HEPES,	  500	  mM	  NaCl,	  250	  mM	  imidazole,	  pH	  7.0.	  
 	  
	  
